ArticleBMC public health2025
Difference in association between dioxin-like compounds and all-cause mortality among non-menopause and menopausal women: a prospective cohort study.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundDioxin-like compounds (DLCs), which have anti-estrogenic properties that disturb estrogen equilibrium in women, have also been associated with increased mortality risk in relevant epidemiological studies. The purpose of this study was to evaluate the differences in the association between serum DLCs and all-cause mortality among non-menopausal and menopausal female populations.
methodsAdults who participated in the 1999-2004 National Health and Nutrition Examination Survey (NHANES) were included. In this study, serum concentrations of 9 DLCs (5 DL-PCBs, 2 PCDDs, and 2 PCDFs) were determined. Participants were observed until December 31, 2019. Stratified analyses were conducted based on sex to investigate sex differences in the association of DLCs with mortality risk. Menstrual stratified analyses were performed to evaluate the characteristics of changes in above association among women before and after menopause.
resultsFinal analysis, 3,523 individuals participated in the study, including 1656 men and 1867 female. Out of the subsequent period of 55,650 person-years, 916 fatalities occurred. A group of seven compounds, namely PCB74, PCB105, PCB118, PCB156, HXCDD, OCDD, and PNCDF, exhibited a significant association with the overall mortality risk in the subject population. Both males and females were at higher risk of mortality from exposure to PCB74, PNCDF, with females being more susceptible. PCB156 and HXCDD were the DLCs that had a positive association with all-cause mortality risk in non-menopausal women.PCB074, PCB105, PCB118, PCB156, and OCDD were the DLCs that had a positive association with all-cause mortality risk in naturally menopausal women.PCB066, PCB074, PCB105, PCB118, PCB156, OCDD, and PNCDF were positively related with all-cause mortality risk in menopausal women who had undergone hysterectomy.
conclusionsAdult population exposure to DLCs corresponds to an increased risk of mortality; in truth, exposure at even low levels raises the probability of death. Women, particularly those who have gone through menopause, are more susceptible to DLCs exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.